Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through Children's Cancer Group, pediatric oncology Group, and Children's Oncology Group: Learning from the past to move forward

Journal of Clinical Oncology

Volumn 34, Issue 25, 2016, Pages 3031-3038

  Lagmay, Joanne P ^a   Krailo, Mark D ^b   Dang, Ha ^b   Kim, AeRang ^d   Hawkins, Douglas S ^e   Beaty, Orren ^f   Widemann, Brigitte C ^g   Zwerdling, Theodore ^c   Bomgaars, Lisa ^h   Langevin, Anne Marie ⁱ   Grier, Holcombe E ^j   Weigel, Brenda ^j   Blaney, Susan M ^h   Gorlick, Richard ^j   Janeway, Katherine A ^j  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Millers Children's Hospital   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Mission Hospital   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; IRINOTECAN; IXABEPILONE; OXALIPLATIN; REBECCAMYCIN; TOPOTECAN;

ADOLESCENT; AGE; ARTICLE; CANCER CONTROL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CONTINUOUS INFUSION; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; OUTCOME ASSESSMENT; PATIENT HISTORY OF CHEMOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; BIOASSAY; BONE NEOPLASMS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; PHASE 2 CLINICAL TRIAL; PROCEDURES; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; BONE NEOPLASMS; CHILD; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84983487344     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.5381     Document Type: Article

References (32)

1. Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600-1606, 1986
2. Meyers PA, Schwartz CL, Krailo M, et al: Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004-2011, 2005
3. Meyers PA, Schwartz CL, Krailo MD, et al: Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival-A report from the Children's Oncology Group. J Clin Oncol 26: 633-638, 2008
4. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
5. Nesbit ME, Gehan EA, Burgert EO, et al: Multimodal therapy for the management of primary, nonmetastatic Ewing sarcoma of bone: A long-term follow-up of the first Intergroup Study. J Clin Oncol 8: 1664-1674, 1990
6. Womer RB, West DC, Krailo MD, et al: Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children's Oncology Group. J Clin Oncol 30:4148-4154, 2012
7. Gehan EA, Tefft MC: Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst 92:179-181, 2000
8. McHugh K, Kao S: Response evaluation criteria in solid tumours (RECIST): Problems and need for modifications in paediatric oncology? Br J Radiol 76:433-436, 2003
9. van Klaveren RJ, Aerts JG, de Bruin H, et al: Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 43:63-69, 2004
10. Trillet-Lenoir V, Freyer G, Kaemmerlen P, et al: Assessment of tumour response to chemotherapy for metastatic colorectal cancer: Accuracy of the RECIST criteria. Br J Radiol 75:903-908, 2002
11. Schuetze SM, Baker LH, Benjamin RS, et al: Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 13:32-40, 2008
12. Goorin AM, Delorey MJ, Lack EE, et al: Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: Analysis of 32 patients. J Clin Oncol 2:425-431, 1984
13. Meyer WH, Schell MJ, Kumar AP, et al: Thoracotomy for pulmonary metastatic osteosarcoma: An analysis of prognostic indicators of survival. Cancer 59:374-379, 1987
14. Saeter G, Høie J, Stenwig AE, et al: Systemic relapse of patients with osteogenic sarcoma: Prognostic factors for long-term survival. Cancer 75: 1084-1093, 1995
15. Ferrari S, Briccoli A, Mercuri M, et al: Postrelapse survival in osteosarcoma of the extremities: Prognostic factors for long-term survival. J Clin Oncol 21:710-715, 2003
16. Hawkins DS, Arndt CA: Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 98:2447-2456, 2003
17. Duffaud F, Digue L, Mercier C, et al: Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy. Eur J Cancer 39:2050-2057, 2003
18. Zwerdling T, Krailo M, Monteleone P, et al: Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: A report from the Children's Oncology Group. Cancer 106:1821-1828, 2006
19. Hawkins DS, Bradfield S, Whitlock JA, et al: Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 47: 790-794, 2006
20. Bomgaars LR, Bernstein M, Krailo M, et al: Phase II trial of irinotecan in children with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 25:4622-4627, 2007
21. Langevin AM, Bernstein M, Kuhn JG, et al: A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 50: 577-580, 2008
22. Bond M, Bernstein ML, Pappo A, et al: A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 50: 254-258, 2008
23. Beaty O, III, Berg S, Blaney S, et al: A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 55: 440-445, 2010
24. Jacobs S, Fox E, Krailo M, et al: Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: A report from the children's oncology group. Clin Cancer Res 16:750-754, 2010
25. Arndt CA, Koshkina NV, Inwards CY, et al: Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: Effects on disease-free survival and immunomodulation. A report from the Children's Oncology Group. Clin Cancer Res 16:4024-4030, 2010
26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
27. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY, John Wiley and Sons, 2002
28. Korn EL, Liu PY, Lee SJ, et al: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534, 2008
29. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
30. Kempf-Bielack B, Bielack SS, Jürgens H, et al: Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23:559-568, 2005
31. Bielack SS, Kempf-Bielack B, Branscheid D, et al: Second and subsequent recurrences of osteosarcoma: Presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 27:557-565, 2009
32. Carroll KJ: Analysis of progression-free survival in oncology trials: Some common statistical issues. Pharm Stat 6:99-113, 2007